BioSpace News Archive

Stealth BioTherapeutics Inc. announced today that Reenie McCarthy, Stealth’s Chief Executive Officer, will participate in a fireside chat at the JMP Citizens Life Sciences Conference in New York on Monday, May 13 at 2:30 p.m. ET and participate in 1x1 meetings with investors.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with prefiltration, an innovative optional accessory for the Tablo® Hemodialysis System.

Allogene Therapeutics, Inc. today announced that it will report first quarter 2024 financial results and provide a business update on May 13, 2024, after the close of the market.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression.

Myomo, Inc. announced that the Centers for Medicare & Medicaid Services, through their regional contractors known as the DME MACs, have remitted and paid lump sum reimbursements to the Company and are beginning to reimburse orthotics and prosthetics providers for MyoPros delivered to Medicare Part B beneficiaries.

Helius Medical Technologies, Inc. announced that the Centers for Medicare & Medicaid Services posted proposed Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rates for the PoNS Controller and Mouthpiece to be discussed at the bi-annual Healthcare Common Procedure Coding System Public Meeting, scheduled for May 29, 2024.

Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, provides an update on the initiative to divest “non-core” assets and increase focus on its core brands and businesses.